Regentis Biomaterials Ltd. (RGNT)
NYSEAMERICAN: RGNT · Real-Time Price · USD
3.255
-0.105 (-3.12%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Company Description
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States.
It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
The company was incorporated in 2004 and is based in Herzliya, Israel.
Regentis Biomaterials Ltd.
| Country | Israel |
| Founded | 2004 |
| IPO Date | Dec 4, 2025 |
| Industry | Other |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Ehud Geller |
Contact Details
Address: 60, Medinat Hayehudim, Entrance C Herzliya, 4676652 Israel | |
| Phone | 972 9 960 1917 |
| Website | regentis.co.il |
Stock Details
| Ticker Symbol | RGNT |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 1912966 |
| CUSIP Number | 001219096 |
| ISIN Number | IL0012190968 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Ehud Geller | Chief Executive Officer |
| Ori Gon | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | 20-F/A | Filing |
| Feb 24, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Feb 24, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | 6-K | Report of foreign issuer |
| Feb 5, 2026 | 6-K | Report of foreign issuer |
| Jan 29, 2026 | 6-K | Report of foreign issuer |
| Jan 20, 2026 | 6-K | Report of foreign issuer |
| Jan 6, 2026 | 6-K | Report of foreign issuer |
| Jan 6, 2026 | 6-K | Report of foreign issuer |